VolitionRX Ltd. Focuses on Epigenetic Cancer Detection

VolitionRX Ltd., a health care equipment and supplies company based in Singapore, continues to make strides in the field of cancer detection. The company specializes in manufacturing epigenetic cancer detection blood tests, which are designed to identify nucleosome patterns unique to cancer found in the blood. These tests aim to distinguish between various cancer types by identifying the main nucleosome varieties that differ among them.

Financial Overview

As of August 12, 2025, VolitionRX Ltd. is listed on the NYSE American with a close price of $0.62. The company’s market capitalization stands at $66,060,000 USD. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of $0.94 on June 22, 2025, and a 52-week low of $0.40 on May 18, 2025. The price-to-earnings ratio is currently at -2.315, reflecting the company’s financial performance and market expectations.

Industry Position

Operating within the Health Care Equipment & Supplies sector, VolitionRX Ltd. is at the forefront of innovative cancer detection technologies. The company’s focus on epigenetic testing positions it uniquely in the market, offering a non-invasive method to detect cancer through blood tests. This approach not only enhances early detection but also aids in the differentiation of cancer types, potentially improving treatment outcomes.

Conclusion

VolitionRX Ltd. remains committed to advancing cancer detection through its specialized epigenetic blood tests. As the company continues to develop and refine its technologies, it holds a promising position in the health care sector, contributing to the global effort in cancer diagnosis and treatment.